Referencia número: HY-111411

IZCZ-3

Name: IZCZ-3
Brand: MedChemExpress
SKU: HY-111411
Price: 150.00 USD
Availability: InStock
Rating: 5 (2 reviews)

2 Cited Publications

Revisión del cliente

Based on 2 publication(s) in Google Scholar

IZCZ-3 is a potent c-MYC transcription inhibitor with antitumor activity.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza : 99.74%
No. CAS: 2223019-53-0
Fòrmula: C₄₆H₄₉N₇O
Peso molecular:715.93

Almacenamiento:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

IZCZ-3 Chemical Structure

No. CAS: 2223019-53-0

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (2)
Solvente y solubilidad
- In Vitro
Protocolo (1)
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

IZCZ-3 is a potent c-MYC transcription inhibitor with antitumor activity^[1].

IC₅₀ & Target

c-MYC transcription^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	IC₅₀	4.2 μM Compound: IZCZ-3	Cytotoxicity against human A375 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human A375 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29474069]
BJ	IC₅₀	15.9 μM Compound: IZCZ-3	Cytotoxicity against human BJ cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human BJ cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29474069]
HBL-100	IC₅₀	11.2 μM Compound: 1; IZCZ-3	Cytotoxicity against human HBL-100 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HBL-100 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 36121464]
HeLa	IC₅₀	2.1 μM Compound: IZCZ-3	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29474069]
HepG2	IC₅₀	6.1 μM Compound: 1; IZCZ-3	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 36121464]
Huh-7	IC₅₀	4.1 μM Compound: IZCZ-3	Cytotoxicity against human Huh7 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human Huh7 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29474069]
MDA-MB-231	IC₅₀	5.1 μM Compound: 1; IZCZ-3	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 36121464]
SiHa	IC₅₀	3.3 μM Compound: IZCZ-3	Cytotoxicity against human SiHa cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human SiHa cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29474069]
U2OS	IC₅₀	6.8 μM Compound: IZCZ-3	Cytotoxicity against human U2OS cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human U2OS cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29474069]

In Vitro

IZCZ-3 (2.1 μM-15.9 μM; 24 hours) significantly inhibits SiHa, HeLa, Huh7, and A375 cancer cell proliferation (IC₅₀s of 3.3, 2.1，4.1, and 4.2 μM, respectively). IZCZ-3 induces only weak growth inhibition in the BJ fibroblasts (IC₅₀=15.9 μM) and mouse mesangial cells (IC₅₀=15.6 μM), suggesting that IZCZ-3 is more effective against cancer cells than against c-MYC-independent normal cells^[1].
? IZCZ-3 (0-5 μM; 12 hours) induces an apparent accumulation of cells in the G0/G1 phase in SiHa cells in a dose-dependent manner^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.

Cell Proliferation Assay^[1]

View Protocol

Cell Line:

SiHa, HeLa, Huh7, and A375 cancer cells (with overexpression of c-MYC protein) and in normal BJ fibroblasts and primary cultured mouse mesangial cells (with relatively low expression of c-MYC protein).
Concentration:

2.1 μM-15.9 μM
Incubation Time:

24 hours
Result:

IC₅₀s of 3.3, 2.1，4.1, and 4.2 μM for SiHa, HeLa, Huh7, and A375 cancer cells; IC₅₀s of 15.9 μM and 15.6 μM for BJ fibroblasts and mouse mesangial cells.

Cell Cycle Analysis^[1]

View Protocol

Cell Line:

SiHa cells
Concentration:

0, 1.25, 2.5, and 5 μM
Incubation Time:

12 hours
Result:

Induced an apparent accumulation of cells in the G0/G1 phase (increasing from 61% to 70%) in a dose-dependent manner.

In Vivo

IZCZ-3 (20, 10, and 5 mg/kg; intraperitoneally; every other day for 24 days) inhibits tumor growth in BALB/c nude mice with SiHa human cervical squamous cancer xenograft^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

BALB/c nude mice (5 weeks old) bearing SiHa human cervical squamous cancer xenograft model^[1]
Dosage:

20, 10, and 5 mg/kg
Administration:

Treated intraperitoneally; every other day for 24 days
Result:

Treatment with 20, 10, and 5 mg/kg resulted in a significant reduction in tumor weight with tumor growth inhibition (TGI) of 69%, 64%, and 57%, respectively. Displayed time-dependent inhibition of tumor growth.

Chemical Information

No. CAS 2223019-53-0
Appearance Solid
Peso molecular 715.93
Fòrmula C₄₆H₄₉N₇O
Color Off-white to pink
SMILES

CN(CC1)CCN1C2=CC=C(C3=C(C4=CC=C(N5CCN(C)CC5)C=C4)N=C(C6=CC(C(C=CC=C7)=C7N8CC)=C8C=C6)N3C9=CC=C(OC)C=C9)C=C2
Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (2)

All WB

Sort by:

Journal Impact Factor

Oncogene

A novel network pharmacology approach for leukaemia differentiation therapy using Mogrify®. [Abstract]

2022 Nov;41(48):5160-5175. PMID: 36271030

IZCZ-3 purchased from MedChemExpress. Usage Cited in: Oncogene. 2022 Nov;41(48):5160-5175. [Abstract]

IZCZ-3 (0.5 μM; 24 h) co-operates with IFNγ to induce differentiation in NB4 cells.
Cell Biol Toxicol

Long non-coding RNA CTSLP8 mediates ovarian cancer progression and chemotherapy resistance by modulating cellular glycolysis and regulating c-Myc expression through PKM2. [Abstract]

2022 Dec;38(6):1027-1045. PMID: 34510316

Solvente y solubilidad

In Vitro:

DMSO : 5 mg/mL (6.98 mM; ultrasonic and warming and heat to 80°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.3968 mL

6.9839 mL

13.9678 mL

5 mM

0.2794 mL

1.3968 mL

2.7936 mL

10 mM

---

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Protocolo

All Animals and Diseases

Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (281 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Hu MH, et al. Discovery of a New Four-Leaf Clover-Like Ligand as a Potent c-MYC Transcription Inhibitor Specifically Targeting the Promoter G-Quadruplex. J Med Chem. 2018 Mar 22;61(6):2447-2459. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.3968 mL	6.9839 mL	13.9678 mL	34.9196 mL
DMSO	5 mM	0.2794 mL	1.3968 mL	2.7936 mL	6.9839 mL

Bioz

Keywords

IZCZ-3

2 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

IZCZ-3

Publications Citing Use of MedChemExpress (MCE) IZCZ-3